Didanosine

Didanosine

Form: Capsules

Strength: 125 mg, 200 mg, 250 mg, 400 mg

Reference Brands: Videx EC®

Category: Anti Viral

Didanosine Capsules, also known by the brand name Videx EC®, are delayed-release antiretroviral medications used in the treatment of HIV-1 infection. Belonging to the Nucleoside Reverse Transcriptase Inhibitor (NRTI) class, Didanosine works by blocking viral replication and is used in combination therapy. Though less commonly prescribed today due to newer alternatives, Didanosine remains relevant in specific treatment regimens and legacy programs. On PharmaB2B platforms, buyers can source WHO-GMP and USFDA-approved formulations in bulk from reliable manufacturers. Ideal for NGOs, tenders, and public sector supply chains in regions where Didanosine is still included in HIV treatment protocols.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.